Morphin 30 Retard (Morphine Sulfate)

Morphine sulfate, the active ingredient in Morphin 30 Retard, is an opioid analgesic presented as a prolonged‑release oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients. GNH USA supplies Morphin 30 Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphin 30 Retard is an opioid analgesic that acts on the mu‑opioid receptor pathway to relieve pain. - Acute severe pain: provides rapid analgesia for postoperative or trauma‑related pain. - Cancer‑related pain: manages moderate to severe pain associated with malignant disease. - Chronic non‑cancer pain: offers sustained relief for long‑term severe pain conditions.

Morphin 30 Retard may cause a range of adverse reactions.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: feeling of queasiness or urge to vomit. - Drowsiness: sedation or increased sleepiness. - Dry mouth: reduced salivation causing oral dryness.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Dependence or addiction: risk of physical or psychological dependence with prolonged use.

When prescribing Morphin 30 Retard, clinicians should consider several safety measures. - Dose titration: start with the lowest effective dose and adjust gradually. - Concomitant CNS depressants: avoid or monitor use with alcohol, benzodiazepines, or other sedatives. - Renal or hepatic impairment: adjust dosing and monitor closely in patients with liver or kidney dysfunction. - History of respiratory disorders: use with caution in asthma, COPD, or sleep apnea. - Pregnancy and lactation: assess risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Morphin 30 Retard can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and sedation. - MAO inhibitors: risk of severe opioid toxicity. - CNS depressants (e.g., benzodiazepines, barbiturates): heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase morphine levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergics: may exacerbate constipation. - Diuretics: may enhance hypotensive effect.